Next-Generation GLP-1 Drugs: What’s New in 2026

The biggest change to the weight loss drug pipeline in 2026 is that several “coming soon” drugs have arrived. Three new options crossed the finish line: oral Wegovy (a semaglutide pill), Wegovy HD (a higher-dose 7.2 mg injection), and Foundayo (orforglipron, the first flexible oral GLP-1 pill). Meanwhile, the next wave of more powerful drugs, retatrutide, CagriSema, amycretin, and survodutide, posted major trial results but remains investigational. Here’s where each one stands as of mid-2026, and what it means for your options.

What Just Became Available

Three approvals reshaped the market in the first months of 2026.

Oral Wegovy (semaglutide 25 mg pill). Approved in December 2025 and launched in January 2026, this is the first oral GLP-1 cleared specifically for weight loss. It produces about 13% to 14% average weight loss, close to the injection, but must be taken on an empty stomach with a 30-minute wait.

Wegovy HD (semaglutide 7.2 mg injection). Approved in March 2026, this higher-dose injection produced about 20.7% average weight loss in its trial, versus about 17.5% on the standard 2.4 mg dose. It’s a step-up for people who have tolerated 2.4 mg and need more weight loss.

Foundayo (orforglipron). Approved in April 2026, this is Eli Lilly’s non-peptide oral pill, and the first GLP-1 you can take any time of day with no food or water restrictions. It produced about 12.4% weight loss at the highest dose and is priced aggressively (around $25 to $149 per month).

What’s Still Coming: The Next Wave

These investigational drugs aim for higher efficacy and posted significant 2026 data, but none is FDA approved or available yet.

Retatrutide (Eli Lilly). A triple agonist hitting GLP-1, GIP, and glucagon. In its Phase 3 TRIUMPH-1 trial reported in 2026, the 12 mg dose produced about 25% average weight loss at 80 weeks (up to about 28% in the on-treatment analysis), with around 30% in people who started with more severe obesity. Lilly expects to file for approval in late 2026 or early 2027, so a launch likely isn’t before 2027 or 2028.

CagriSema (Novo Nordisk). A fixed-dose combination of semaglutide and the amylin analog cagrilintide. It was submitted to the FDA in December 2025, with a decision expected by late 2026. Its REDEFINE 1 trial showed about 20% to 23% weight loss, but in a head-to-head trial (REDEFINE 4) it fell short of matching tirzepatide, posting about 23% versus tirzepatide’s 25.5%.

Amycretin (Novo Nordisk). A single molecule combining GLP-1 and amylin, in development as both a weekly injection and a daily pill. Early obesity data reached about 22% weight loss, and a Phase 2 diabetes trial reported in late 2025 supported moving both formulations into Phase 3 in 2026. Any approval is likely 2028 at the earliest.

Survodutide (Boehringer Ingelheim / Zealand Pharma). A GLP-1/glucagon dual agonist notable for its effects on fatty liver disease (MASH). Its Phase 2 obesity data reached roughly 15% to 19% weight loss, and it’s in Phase 3 (the SYNCHRONIZE program) for both obesity and liver disease.

Others on the Horizon

Several more candidates are progressing. Pemvidutide (Altimmune), a GLP-1/glucagon agonist, showed about 15.6% weight loss in Phase 2 with an emphasis on preserving lean mass. MariTide (Amgen) is a once-monthly injection in late-stage testing. VK2735 (Viking Therapeutics) is a dual GIP/GLP-1 agonist with strong early data and both injectable and oral forms in development. CT-388 (Roche) is in mid-stage trials. On the oral side, Pfizer’s danuglipron was discontinued, underscoring how difficult oral small-molecule GLP-1 development has been, while other companies pursue their own oral programs. The GLP-1 market overview covers the competitive picture in more detail.

Pipeline Snapshot (Mid-2026)

What This Means for You

The practical takeaway hasn’t changed much despite all the activity: effective, proven treatments are available today, and the strongest options remain the injectables, with tirzepatide leading on weight loss and now Wegovy HD offering a higher-dose semaglutide route. The new pills (oral Wegovy and Foundayo) add genuine choice for people who prefer to avoid needles, at the cost of somewhat lower average weight loss. The next wave of more powerful drugs is coming, but waiting years for them usually doesn’t make sense when proven options exist now and switching later is straightforward. You can see what tirzepatide achieves over a few months or read how survodutide’s dual mechanism works if you want to go deeper.

A licensed provider can help you match an available medication to your goals. TrimRx’s intake quiz is a simple place to start.

This article is for general educational purposes only and is not medical advice. Investigational drugs named here (retatrutide, CagriSema, amycretin, survodutide) have not been approved by the FDA and are not available, including through TrimRx. Approved medications carry risks and are not appropriate for everyone. Weight loss figures reflect clinical trial findings and are not guarantees of individual results. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment.